SCHEMBL17215457

SCHEMBL17215457

N#Cc1cccc(/[C]=N\OCc2cccc(C#N)c2)c1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MRGPRX4 Q96LA9 2/20 0.47
▸ FFAR1 O14842 1/20 0.44
▸ FFAR4 Q5NUL3 1/20 0.44
▸ GLA P06280 1/20 0.41
▸ MAOB P27338 4/20 0.40
▸ MAOA P21397 3/20 0.40
▸ CYP19A1 P11511 1/20 0.39
▸ CYP11B1 P15538 1/20 0.39
▸ CYP11B2 P19099 1/20 0.39
▸ HRH3 Q9Y5N1 1/20 0.39
▸ HTR6 P50406 2/20 0.39
▸ CYP4F2 P78329 1/20 0.39
▸ CYP4A11 Q02928 1/20 0.39
▸ GRM5 P41594 2/20 0.39
▸ KDM1A O60341 1/20 0.39
▸ ALKBH1 Q13686 1/20 0.39
▸ CCR5 P51681 1/20 0.39
▸ ENPP2 Q13822 1/20 0.39
▸ SLC6A4 P31645 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17215460 1.00 MRGPRX4 (0.47) MRGPRX4FFAR1FFAR4GLAMAOB
SCHEMBL17217496 0.92 MRGPRX4 (0.46) MRGPRX4FFAR1FFAR4GLAMAOB
SCHEMBL17217497 0.92 MRGPRX4 (0.46) MRGPRX4FFAR1FFAR4GLAMAOB
SCHEMBL17217178 0.92 FFAR1 (0.46) MRGPRX4FFAR1FFAR4GLAMAOB
SCHEMBL17217417 0.92 MAOB (0.46) MRGPRX4FFAR1FFAR4GLAMAOB
SCHEMBL17217180 0.92 FFAR1 (0.46) MRGPRX4FFAR1FFAR4GLAMAOB
SCHEMBL17217419 0.92 MAOB (0.46) MRGPRX4FFAR1FFAR4GLAMAOB
SCHEMBL17219555 0.91 MRGPRX4 (0.52) MRGPRX4MAOBMAOAGRM5SLC6A4
SCHEMBL17216883 0.91 MRGPRX4 (0.43) MRGPRX4FFAR1FFAR4GLAMAOB
SCHEMBL17216886 0.91 MRGPRX4 (0.43) MRGPRX4FFAR1FFAR4GLAMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2940012-B1 TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF SUMITOMO CHEMICAL CO (JP) 2019-01-30 — — EP disclosed
US-9560850-B2 Tetrazolinone compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-02-07 — — US disclosed
US-20150336908-A1 TETRAZOLINONE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2015-11-26 — — US disclosed
EP-2940012-A1 TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF Sumitomo Chemical Company Limited (JP) 2015-11-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150336908-A1 TETRAZOLINONE COMPOUND AND USE THEREOF RTN3, CYP51A1, TCOF1 MRGPRX4 1822/4885FFAR1 1045/4885FFAR4 2119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback